Intercept Tries to Outrun Pharma in Race for the Next Blockbuster

Since then, Pruzanski, founder and chief executive of Intercept Pharmaceuticals Inc., has hunted for a treatment for the disorder, known as nonalcoholic steatohepatitis, or NASH. The condition, marked by a buildup of fat and scarring in the liver, is thought to afflict 50 million Americans, many of them already sick from obesity and diabetes.